| TMPRSS2-ERG Gene Fusion Status | ||
---|---|---|---|
Characteristics | Not Scored1 | Positive | Negative |
 | n = 158 | n = 76 | n = 138 |
Age at diagnosis | Â | Â | Â |
   Mean (SD) | 61.2 (7.4) | 59.3 (6.3) | 59.9 (7.2) |
   Range | 40 – 86 | 45 – 88 | 45 – 86 |
Gleason score (%) | Â | Â | Â |
   2 - 7 (3+4) | 138 (87.3) | 63 (82.9) | 115 (83.3) |
   7 (4+3) - 10 | 17 (10.8) | 12 (15.8) | 19 (13.8) |
   Missing | 3 (1.9) | 1 (1.3) | 4 (2.9) |
Stage (%) | Â | Â | Â |
   Local | 121 (76.6) | 57 (75) | 106 (76.8) |
   Regional | 37 (23.4) | 18 (23.7) | 29 (21.0) |
   Distant | 0 (0) | 1 (1.3) | 3 (2.2) |
PSA value at diagnosis (ng/ml) (%) | Â | Â | Â |
   0 – 9.9 | 92 (58.2) | 52 (68.4) | 91 (65.9) |
   ≥ 10.0 | 41 (26.0) | 16 (21.1) | 29 (21.0) |
   Missing | 25 (15.8) | 8 (10.5) | 18 (13.1) |
Vital status (%) | Â | Â | Â |
   Alive | 129 (81.7) | 65 (85.5) | 119 (86.2) |
   Deceased |  |  |  |
Prostate cancer-specific death | 4 (2.5) | 6 (7.9) | 6 (4.4) |
Other cause of death | 25 (15.8) | 5 (6.6) | 12 (8.7) |
   Missing | 0 (0) | 0 (0) | 1 (0.7) |
Fusion Type | Â | Â | Â |
   Translocation | - | 38 (50) | - |
   Deletion | - | 38 (50) | - |
Fusion Number | Â | Â | Â |
   Single | - | 65 (85.5) | - |
   Multiple | - | 11 (14.5) | - |
Survival Time (years) (SD) | 11.5 (2.6) | 12.0 (2.6) | 11.4 (3.1) |